Comparison of three different chemotherapy regimens containing epirubicin in hormone-refractory prostate cancer patients

Basit Öğe Kaydı
dc.authoridTopaloglu, Hikmet/0000-0002-7110-4822
dc.contributor.authorErsoy, Hamit
dc.contributor.authorYigitbasi, Orhan
dc.contributor.authorSagnak, Levent
dc.contributor.authorTopaloglu, Hikmet
dc.contributor.authorKiper, Ahmet
dc.date.accessioned2024-09-18T20:26:48Z
dc.date.available2024-09-18T20:26:48Z
dc.date.issued2008
dc.departmentHatay Mustafa Kemal Üniversitesien_US
dc.description.abstractWe compared three different chemotherapy regimens containing epirubicin in hormone-refractory prostate cancer (HRPC) patients. Sixty-nine patients with HRPC were randomized into three groups. The first group (22 patients) received 30 mg/m(2)/week i.v. epirubicin for 8 weeks. The second group (24 patients) received 30 mg/m(2)/week i.v. epirubicin for 8 weeks followed by monthly maintenance therapy for 4-6 months. The third group (23 patients) received oral estramustine phosphate (EMP) at a dose of 840 mg/day together with weekly and monthly maintenance epirubicin. The response rates, mean survival times, and toxicity were determined. Within the first 3 months, pain and performance scores were improved by at least one degree in all the groups. One patient in group two and three patients in group three had complete response. Partial response rates were 23% in group 1, 25% in group 2, and 17% in group 3. Stable disease rates were 41% in group 1, 33% in group 2, and 26% in group 3. The progression rates within the first 3 months were 36% in group 1, 38% in group 2, and 44% in group 3. None of the patients developed complications that were significant enough to terminate the treatment. Two patients in group 3 died of cardiotoxicity. The mean survival times were 10.1, 15.8, and 16.1 months in groups 1, 2, and 3, respectively. It was determined that weekly and maintenance epirubicin treatment protocol, and estramustine treatment protocol in addition to this treatment, was only meaningfully more effective against weekly epirubicin treatment in the statistical sense (0.01 < p < 0.05). However, due to the complications of EMP, which influence the quality of life, we believe that this was usable only when measures were adopted against these effects.en_US
dc.identifier.doi10.1100/tsw.2008.90
dc.identifier.endpage597en_US
dc.identifier.issn1537-744X
dc.identifier.pmid18604442en_US
dc.identifier.scopus2-s2.0-45749141662en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage586en_US
dc.identifier.urihttps://doi.org/10.1100/tsw.2008.90
dc.identifier.urihttps://hdl.handle.net/20.500.12483/10541
dc.identifier.volume8en_US
dc.identifier.wosWOS:000256706400004en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherThescientificworld Ltden_US
dc.relation.ispartofThescientificworldjournalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjecthormone-refractory prostate canceren_US
dc.subjectepirubicinen_US
dc.subjectestramustine phosphateen_US
dc.titleComparison of three different chemotherapy regimens containing epirubicin in hormone-refractory prostate cancer patientsen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Tam Metin / Full Text
Boyut:
1.21 MB
Biçim:
Adobe Portable Document Format
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu